Parkman Healthcare Partners’s Charles River Laboratories CRL Stock Holding History

Parkman Healthcare Partners’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-17,697	Closed	-$4.8M	–	95
2024 Q1	$4.8M	Buy	+17,697	New	+$4.23M	0.59%	56
2023 Q4	–	Sell	-44,160	Closed	-$8.65M	–	94
2023 Q3	$8.65M	Buy	+44,160	New	+$9.07M	1.59%	18
2022 Q2	–	Sell	-10,000	Closed	-$2.84M	–	81
2022 Q1	$2.84M	Sell	10,000 -15,901	-61%	-$4.9M	0.83%	41
2021 Q4	$9.76M	Buy	25,901 +901	+4%	+$350K	2.15%	18
2021 Q3	$10.3M	Sell	25,000 -27,245	-52%	-$11.3M	2.61%	9
2021 Q2	$19.3M	Buy	52,245 +2,245	+4%	+$750K	4.22%	3
2021 Q1	$14.5M	Buy	50,000 +10,334	+26%	+$2.87M	3.36%	4
2020 Q4	$9.91M	Sell	39,666 -339	-0.8%	-$80.7K	2.54%	10
2020 Q3	$9.06M	Buy	40,005 +5	+0%	+$1.04K	2.4%	10
2020 Q2	$6.97M	Buy	+40,000	New	+$6.38M	1.96%	19

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Parkman Healthcare Partners's CRL Position: Q2 2024 in Review

Parkman Healthcare Partners sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 17,697 shares — an estimated $4.8M sold.

Parkman Healthcare Partners first reported a position in CRL in Q2 2020 and held it in 10 quarters. The position peaked at $19.3M in Q2 2021. 665 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

Parkman Healthcare Partners reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
Parkman Healthcare Partners sold 17,697 Charles River Laboratories shares in Q2 2024, an estimated $4.8M.
Parkman Healthcare Partners first reported a position in Charles River Laboratories in Q2 2020 and held it in 10 quarters.
Parkman Healthcare Partners's Charles River Laboratories position peaked at $19.3M in Q2 2021.
665 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Parkman Healthcare Partners's 13F filing for Q2 2024, filed 14 Aug 2024.